Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study
Saved in:
| Published in: | Journal of Asthma and Allergy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1864030191789015045 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Journal of Asthma and Allergy |
| description | |
| discipline_display | Medical & Health Sciences |
| discipline_facet | Medical & Health Sciences |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:35793 |
| institution | FRELIP |
| journal_source_facet | Journal of Asthma and Allergy |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study — — — — — Allergology and Immunology Clinical Medicine Medical & Health Sciences |
| sub_discipline_display | Clinical Medicine |
| sub_discipline_facet | Clinical Medicine |
| subject_display | — — — — — Allergology and Immunology Clinical Medicine Medical & Health Sciences — — — — — Allergology and Immunology Clinical Medicine Medical & Health Sciences |
| subject_facet | — — — — — Allergology and Immunology Clinical Medicine Medical & Health Sciences |
| title | Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study |
| title_auth | Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study |
| title_full | Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study |
| title_fullStr | Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study |
| title_full_unstemmed | Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study |
| title_short | Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study |
| title_sort | feasibility of a 50% dosing interval extension of anti–il-5 biologics in patients with severe asthma in clinical remission: a real-world validation study |
| topic | — — — — — Allergology and Immunology Clinical Medicine Medical & Health Sciences |
| url | https://www.dovepress.com/feasibility-of-a-50-dosing-interval-extension-of-antiil-5-biologics-in-peer-reviewed-fulltext-article-JAA |